TLR7 and anogenital human papillomavirus infection: This is illustrated by the promise of nucleic acid sensor agonists such as the TLR7 agonist, imiquimod, that has been approved for the treatment of genital warts (HPV), and the recent “shock and kill” strategies aimed at eradicating latent HIV viral reservoirs using TLR7 and TLR9 ligands, such as GS-9620 (vesatolimod) and MGN1703 (lefitolimod), respectively, to initiate viral reactivation and promote immune-mediated killing of infected cells (42–44).